<?xml version="1.0" encoding="UTF-8"?>
<ref id="CIT0015">
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name name-style="western">
    <surname>La Rosée</surname>
    <given-names>F.</given-names>
   </name>, 
   <name name-style="western">
    <surname>Bremer</surname>
    <given-names>H. C.</given-names>
   </name>, 
   <name name-style="western">
    <surname>Gehrke</surname>
    <given-names>I.</given-names>
   </name>, 
   <name name-style="western">
    <surname>Kehr</surname>
    <given-names>A.</given-names>
   </name>, 
   <name name-style="western">
    <surname>Hochhaus</surname>
    <given-names>A.</given-names>
   </name>, 
   <name name-style="western">
    <surname>Birndt</surname>
    <given-names>S.</given-names>
   </name>, 
   <name name-style="western">
    <surname>Fellhauer</surname>
    <given-names>M.</given-names>
   </name>, 
   <name name-style="western">
    <surname>Henkes</surname>
    <given-names>M.</given-names>
   </name>, 
   <name name-style="western">
    <surname>Kumle</surname>
    <given-names>B.</given-names>
   </name>, 
   <name name-style="western">
    <surname>Russo</surname>
    <given-names>S. G.</given-names>
   </name>, &amp; 
   <name name-style="western">
    <surname>La Rosée</surname>
    <given-names>P.</given-names>
   </name>
  </person-group> (
  <year>2020</year>). 
  <article-title>The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperin–ammation</article-title>. 
  <source>
   <italic toggle="yes">Leukemia</italic>,
  </source> (
  <issue>7</issue>), 
  <fpage>1805</fpage>–
  <lpage>1811</lpage>. 
  <pub-id pub-id-type="doi">10.1038/s41375-020-0891-0</pub-id>
  <pub-id pub-id-type="pmid">32518419</pub-id>
 </mixed-citation>
</ref>
